Squamous cell carcinoma is the most common malignant tumor of the penis. The new World Health Organization (WHO) classifies it into two types: non-HPV-related and HPV-related. There is a certain proportion of recurrence and metastasis after the first operation on the tumor.
Neuroendocrine tumours (NET) are extremely rare and aggressive. Although they commonly affect intestine, many organs may be involved such as pancreas, lung or urinary tract. Bladder is rarely involved.
The Vesical Imaging Reporting and Data System (VI-RADS) was launched in 2018 to standardize reporting of magnetic resonance imaging (MRI) for bladder cancer (BC). This study aimed to prospectively validate VI-RADS using a next-generation MRI scanner and to investigate the usefulness of denoising deep learning reconstruction (dDLR).
A prospective randomized trial (LEA AUO AB 25/02) found no survival benefit in extended compared with limited pelvic lymph node dissection (PLND) templates in bladder cancer (BCa) patients treated with radical cystectomy (RC).
The presence of detrusor muscle (DM) is essential for accurate staging of T1 cancers. DM presence can be a quality indicator of transurethral resection of bladder tumor (TURBT) for NMIBC. We hypothesized that increasing surgeon awareness of personal and institutional DM sampling rates could improve resection quality and long-term oncologic outcomes.
Bladder cancer is the ninth most common malignancy worldwide with over 330,000 cases diagnosed every year. The standard surgical treatment offered to patients diagnosed with muscle-invasive bladder cancer or high-risk non-muscle-invasive bladder cancer is radical cystectomy with pelvic lymph node dissection. This can be performed laparoscopically, robotically, or in an open fashion. Open radical cystectomy […]
Alicia Morgans: Hi. My name is Alicia Morgans and I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago, Illinois in the United States. I’m so excited to have here with me today, a friend and colleague, Dr. Kala Sridhar, who is an associate professor of medicine at the University […]
Alicia Morgans: Hi, my name is Alicia Morgans. I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago in the US. I’m so excited to have here with me today, Dr. Srikala Sridhar, who is an Associate Professor of Medicine at the University of Toronto at the Princess Margaret Cancer […]
The European Cancer Organisation’s major new report, Viral Protection: Achieving the Possible. A Four-Step Plan for Eliminating HPV Cancers in Europe (published today), calls for urgent action to eliminate most of the 87,000 cancer cases caused in men and women by HPV (human papillomavirus) each year across over 50 countries in the WHO European Region. […]
Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient’s quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant prostate cancer) patients with symptomatic bone metastases.
